Mesalamine-Induced Myopericarditis: A Case Report and Literature Review
Loading...
Authors
Taha, Mohamed E.
Abdalla, Abubaker O.
Al-Khafaji, Jaafar
Malik, Samira
Issue Date
2019
Type
Article
Language
Keywords
Chest pain , cmr , Mesalamine , Myopericarditis , Ulcerative colitis
Alternative Title
Abstract
Inflammation of the myocardium (myocarditis) or pericardium (pericarditis) or both (myopericarditis) as side effects of mesalamine, a drug widely used in the treatment of inflammatory bowel disease, is a rare, but potentially lethal complication. We report a case of myopericarditis occurring in a young Caucasian woman 14 days following initiation of mesalamine therapy for treatment of a newly diagnosed ulcerative colitis (UC). She presented with pleuritic chest pain, elevated troponin levels and pre-syncope. The diagnosis of myopericarditis was made based on the clinical features, electrocardiogram (EKG) and cardiac magnetic resonance, which showed trace pericardial effusion. The patient's symptom and condition were dramatically improved upon discontinuing mesalamine, and a full recovery was achieved. Mesalamine-induced inflammation of the myocardium (myocarditis) or pericardium (pericarditis) or both (myopericarditis) is rare, but has fatal side effects. Early recognition of these side effects by clinicians and patients is important to prevent progression of the inflammation. Furthermore, patients should be educated to seek urgent medical attention if cardiac symptoms arise.
Description
Citation
Taha, M. E., Abdalla, A., Al-Khafaji, J., & Malik, S. (2019). Mesalamine-Induced Myopericarditis: A Case Report and Literature Review. Cardiology Research, 10(1), 59�"62. doi:10.14740/cr820
Publisher
License
Creative Commons Attribution-NonCommercial 4.0 International
Journal
Volume
Issue
PubMed ID
DOI
ISSN
1923-2829